SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, announced the launch of two studies to validate its innovative GLP-1 patient stratification diagnostic platform. These studies aim to transform obesity and type 2 diabetes care by enabling healthcare providers to identify individuals most likely to benefit from GLP-1 therapies, optimizing treatment outcomes and reducing unnecessary costs.

SOLVD's focus on brain reward pathways is central to this development, which enables insights into the genetic underpinnings of both metabolic conditions and behavioral health. Powered by advanced AI algorithms, this approach leverages genetic markers and clinical records associated with GLP-1 to help healthcare providers identify patients most likely to respond to GLP-1 therapies, potentially transforming treatment protocols for a condition that affects one in eight people globally, while advancing the understanding of how these neural pathways influence a range of health conditions.

Building on the success of AvertD, the first and only FDA-approved genetic test for assessing the genetic risk of developing Opioid Use Disorder, which also targets the brain's reward pathways, SOLVD's GLP-1 therapeutic approach benefits from similar mechanisms. AvertD’s FDA PMA approval serves as a precedent, providing a platform that can be leveraged to enhance the clinical adoption and regulatory submission of GLP-1-based solutions for metabolic and behavioral health.

"As the worldwide prevalence of obesity and type 2 diabetes continues to grow, the need for more targeted, personalized treatment methods becomes increasingly critical," said SOLVD Health Founder and President Dr. Keri Donaldson. "Our diagnostic technology aims to bring precision medicine to GLP-1 therapies to help healthcare providers optimize treatment outcomes and reduce unnecessary costs."

The AI-driven technology is designed to identify individuals most likely to respond to specific GLP-1 therapeutics, unlocking precise patient stratification and enabling personalized treatment plans. This approach aligns with SOLVD Health’s proven platform strategy, which has already demonstrated the value of genetic insights in tailoring patient care through its existing test portfolio.

“By examining the genetic underpinnings of GLP-1 therapeutic response, we’re creating a tool that could fundamentally change how we address obesity and type-2 diabetes treatments," added Dr. Donaldson. "This technology can improve patient selection criteria, enhancing clinical trial efficiency and commercializing targeted therapies."